Clinical trial NCT04450693: Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)
Official title: A Multicenter Phase 3 Confirmatory Trial of Biotherapy Using Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Diabetic Foot Infection
Non-healing Wound
Non-healing Diabetic Foot Ulcer
Lead sponsor: BioTissue Holdings, Inc
Sponsor class: INDUSTRY
First posted: 2020-06-29
Enrollment: 106
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: It is hypothesized that application at 4-week or greater intervals of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer (DFU) will, with concomitant management of infection, result in a higher rate of wounds showing complete healing within 25 weeks of initiating therapy, compared with standard care alone. This second confirmatory Phase 3 study examines a population of diabetic foot ulcer patients having adequate perfusion, with or without neuropathy, and a high suspicion of associated osteomyelitis in a complex, high grade wound.

Detailed description: This trial is designed as a confirmatory study of the benefits and risks of TTAX01 when used in the treatment of Wagner Grades 3 and 4 DFU. Experience with the use of a cryopreserved umbilical cord (UC) product in treating such wounds, both prior to this IND and under this IND, has indicated that a frequency of application of no shorter than every 4 weeks is associated with better than expected outcomes. Although treatment cannot be blinded, a "standard care only" arm is included to control for the benefits of aggressive baseline debridement combined with aggressive (6 weeks systemic) antibiotics. Current treatment guidelines indicate that aggressive debridement plus 1-2 weeks of antibiotics, or, minor debridement plus 6 weeks of antibiotics, would produce equivalent outcomes, although the evidence is not strong. By utilizing both maximum debridement and maximum antimicrobial therapy, the standard care described in this protocol may result in healing rates somewhat superior to current standard practice.

The design of this second confirmatory study is matched to the design of the Phase 2 efficacy study TTCRNE-1501, with the exception of extending the primary endpoint from a landmark analysis at 16 to a "wound survival" analysis through 26 weeks, utilizing a proportional risk analysis rather than a simple test of proportions. This design consideration is based on analysis of previous studies (see Background section), and a desire to fold data from every visit into the primary analysis, rather than generating an excessive number of secondary endpoints.

Eligibility criteria: Inclusion Criteria:

* The subject has signed the informed consent form
* The subject is male or female, at least 18 years of age inclusive at the date of Screening
* The subject has confirmed diagnosis of Type I or Type II diabetes
* The subject's index ulcer is located on the plantar surface, inter digital, heel, lateral or medial surface of the foot
* The subject has an index ulcer with visible margins having an area ≤ 12.0 cm2 when measured by the electronic measuring device at Screening
* The subject's index ulcer extends beyond the dermis, into subcutaneous tissue with evidence of exposed bone, tendon, muscle and/or joint capsule
* The subject presents with history, signs or symptoms leading to a clinical suspicion of osteomyelitis in the opinion of the Investigator supported by positive Probe to Bone (PTB) and any of the following: radiographic (X-ray, Magnetic Resonance Imaging (MRI), or bone scan) or evidence of bone necrosis
* The subject has an Ankle-Brachial Index ≥ 0.7 to ≤ 1.3 or TcPO2 ≥ 40 mmHg on the dorsum of the affected foot, or Great Toe Pressure ≥ 50 mmHg
* The subject is under the care of a physician for the management of Diabetes Mellitus
* The subject is willing to return for all mandatory visits as defined in the protocol
* The subject is willing to follow the instructions of the trial Investigator

Exclusion Criteria:

* The subject's index ulcer is primarily located on the dorsal surface of the foot
* The subject's index ulcer can be addressed by primary closure through the completion of the initial or staged surgical procedure
* The subject has a contralateral major amputation of the lower extremity
* The subject has a glycated hemoglobin A1c (HbA1c) level of \> 12% †
* The subject has been on oral steroid use of \> 7.5 mg daily for greater than seven (7) consecutive days in 30 days before Screening
* The subject has been on parenteral corticosteroids, or any cytotoxic agents for seven consecutive days in the period of 30 days before Screening
* The subject is currently taking the type 2 diabetes medicine canagliflozin (Invokana™, Invokamet™, Invokamet XR™)
* The subject has malignancy or a history of cancer, other than non-melanoma skin cancer, in five years before Screening
* The subject is pregnant
* The subject is a nursing mother
* The subject is a woman of child-bearing potential who is unwilling to avoid pregnancy or use an appropriate form of birth control (adequate birth control methods are defined as: topical, oral, implantable, or injectable contraceptives; spermicide in conjunction with a barrier such as a condom or diaphragm; intrauterine contraceptive device; or surgical sterilization of partner).
* The subject is unable to sustain off-loading as defined by the protocol
* The subject has an allergy to primary or secondary dressing materials used in this trial
* The subject has an allergy to glycerol
* The subject's index ulcer is over an acute Charcot deformity
* The subject has had previous use of NEOX®, CLARIX®, or TTAX01 applied to the index ulcer
* Per Investigator's discretion the subject is not appropriate for inclusion in the trial, e.g., undergoing surgical treatments listed in the protocol or the subject currently has sepsis, i.e., life-threatening organ dysfunction caused by a dysregulated host response to infection

Primary outcomes:
measure: Complete wound healing
timeFrame: over 25 weeks
Secondary outcomes:
measure: Wound durability
timeFrame: by Week 26
measure: Limb preservation
timeFrame: by Week 26
measure: Patient-reported mobility
timeFrame: Baseline to End of Study (approximately 26 weeks)
Other outcomes:
Locations:
city: Guntersville
country: United States
facility: LakeView Clinical Research
state: Alabama
city: Tucson
country: United States
facility: Banner University Medical Center Tucson
state: Arizona
city: Los Angeles
country: United States
facility: Clemente Clinical Research
state: California
city: Mather
country: United States
facility: VA Northern California Health Care System
state: California
city: Palmdale
country: United States
facility: CureCentric
state: California
city: Whittier
country: United States
facility: PIH Health
state: California
city: Deland
country: United States
facility: Midland Florida Clinical Research Center
state: Florida
city: Delray Beach
country: United States
facility: Delray Physician Care Center
state: Florida
city: O'Fallon
country: United States
facility: Gateway Clinical Trials, LLC
state: Illinois
city: Boston
country: United States
facility: Beth Israel Deaconess Medical Center
state: Massachusetts
city: Reno
country: United States
facility: Reno Orthopedic Clinic
state: Nevada
city: Westwood
country: United States
facility: Curalta Foot and Ankle
state: New Jersey
city: Circleville
country: United States
facility: Cutting Edge Research, LLC
state: Ohio
city: Dallas
country: United States
facility: University of Texas Southwestern Medical Center
state: Texas
city: Houston
country: United States
facility: Advantage Foot Care of Houston
state: Texas
city: Houston
country: United States
facility: Biolife Genetics Research
state: Texas
Study officials:
affiliation: Chief Medical Officer
name: Seema Kumbhat, MD
role: STUDY_CHAIR
References: